recombinant FSH
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT03846544 | Oct 2019 → Sep 2021 | infertility disorder | CRG UZ Brussel | Completed | Missed primary |
| Phase not applicable3 trials | ||||||
| — | NCT07409493 | Jan 2026 → Jun 2028 expected | infertility disorder | Hanoi Medical University | Recruiting | No outcome recorded |
| — | NCT02478775 | Jul 2015 → Jun 2021 | infertility disorder, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01421095 | Jan 2011 → Dec 2026 expected | cancer, infertility disorder | University of California, San Diego | Active not recruiting | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 1/2 | NCT00823121 Comparator | Aug 2008 → Feb 2009 | — | Yazd Research & Clinical Center for Infertility | Unknown | No outcome recorded |
| Phase 3 | NCT01816321 Comparator | Mar 2013 → May 2016 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | Missed primary |
| Phase 3 | NCT00884221 Comparator | Jul 2009 → Jul 2010 | infertility disorder | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT07121751 Comparator | Sep 2025 → Aug 2026 overdue | infertility disorder | Dunamenti REK Istenhegyi IVF Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04724486 Background | Aug 2020 → Mar 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727684 Background | Aug 2020 → Feb 2022 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724343 Background | Dec 2019 → Jan 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727671 Background | Dec 2019 → Aug 2021 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT02554279 Comparator | Aug 2015 → Jan 2017 | infertility disorder | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01345812 Comparator | Apr 2011 → Jul 2012 | — | University of Aarhus | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01267604 Comparator | Dec 2010 → Dec 2013 | infertility disorder | AGUNCO Obstetrics and Gynecology Centre | Withdrawn | No outcome recorded |
| Phase 4 | NCT02437032 Comparator | Apr 2009 → Sep 2012 | infertility disorder | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT00830492 Comparator | Jan → Dec 2008 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
| — | NCT05089344 Background | Oct 2021 → Oct 2022 | female infertility | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| — | NCT04325295 Comparator | Dec 2020 → Jun 2022 | anovulation, polycystic ovary syndrome | Assiut University | Unknown | No outcome recorded |
| — | NCT02244866 Comparator | Oct 2012 → Apr 2014 | infertility disorder | Vietnam National University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant FSH | “150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866 ↗19“225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR).” NCT03846544 ↗ “150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.” NCT00830492 ↗ “Patients receive recombinant FSH starting from day 2-3 of menstrual cycle” NCT07409493 ↗ “same recombinant FSH dose as in her prevoius cycle” NCT07121751 ↗ |
| Known as | Gonal F | “recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU” NCT05089344 ↗1“150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.” NCT00830492 ↗ |
| Known as | recombinant Follicle-Stimulating Hormone | “The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of...” NCT04727684 ↗3“Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm...” PMID 32416978 ↗ May 2020 “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724486 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH)” NCT04727671 ↗ |
| Known as | rFSH | “The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of...” NCT04727684 ↗8“test the hypothesis that intravenous (IV) administration of pulsatile recombinant follicle-stimulating hormone (rFSH) can overcome the clinically evident dysfunctional...” PMID 37276947 ↗ Jun 2023 “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724343 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724486 ↗ “225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR).” NCT03846544 ↗ “compared with daily recombinant FSH (rFSH) in young poor responders?” PMID 29040589 ↗ Nov 2017 “highly purified menotropin (hphMG) and recombinant FSH (rFSH)” PMID 22244781 ↗ Jan 2012 “recombinant Follicle-Stimulating Hormone (r-FSH)” NCT04727671 ↗ “Recombinant FSH (rFSH)” NCT01267604 ↗ |
| Action | Restore | “Pulsatile FSH can partially correct the relative hypogonadotropic hypogonadism of obesity” PMID 37276947 ↗ Jun 2023 |
| Modality | Protein / enzyme biologic | “recombinant FSH” NCT00823121 ↗ |
| Route | Subcutaneous | “150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.” NCT00830492 ↗ |